Patients on Buprenorphine Must Be Counseled About Serious Dental Risks and Preventive Measures
Patients receiving sublingual or buccal buprenorphine should be explicitly warned that this medication can cause severe tooth decay, cavities, oral infections, and tooth loss, and must be instructed to rinse their mouth with water and swallow immediately after the tablet/film dissolves, wait at least 1 hour before brushing, and receive fluoride supplementation with more frequent dental monitoring.
The Evidence Base
The FDA issued a drug safety communication in 2022 specifically warning about dental adverse events with transmucosal buprenorphine formulations 1. This is not theoretical—multiple recent studies confirm significantly elevated risk:
- Transmucosal formulations (sublingual/buccal) show 14-24 times higher reporting of dental disorders compared to other medications, with sublingual buprenorphine/naloxone showing a reporting odds ratio of 19.47 2
- A 2026 propensity-matched cohort study found 36% increased risk of dental adverse events (adjusted HR 1.36) among buprenorphine users 3
- A 2025 study demonstrated 24-30% higher risk of new oral health problems at both 1-year and 5-year follow-up 4
The mechanism appears related to prolonged oral exposure—rat studies show greater buprenorphine accumulation in salivary glands with sublingual administration, creating sustained acidic exposure that promotes decay 5.
Specific Patient Instructions
Immediate Post-Dose Protocol
- Rinse mouth thoroughly with water and swallow once the tablet/film has completely dissolved
- Wait at least 1 hour before brushing teeth to avoid abrading acid-softened enamel 6
- Do not eat or drink until medication fully dissolves 1
Daily Preventive Measures
- Brush twice daily with fluoride toothpaste 7, 6
- Prescribe fluoride supplements (beyond standard toothpaste) 6
- Drink fluoridated water if available 7
Enhanced Monitoring
- Increase dental visit frequency beyond standard 6-month intervals 6
- Conduct caries risk assessments at each visit 6
- Complete oral history and assessment before initiating buprenorphine 8
Critical Caveats
Do not discontinue buprenorphine due to dental concerns—this is life-saving medication for opioid use disorder, and the mortality risk from untreated OUD far exceeds dental risks 6. The dentist's role includes ensuring patients continue their medication-assisted treatment 6.
The risk appears specific to transmucosal formulations. Injectable buprenorphine formulations do not carry the same dental risk profile 5, 2, though access barriers currently limit their use.
While one case report describes oral cavity cancer at a sublingual placement site after 13 years of use 9, this represents a single case and causation cannot be established. The primary concern remains tooth decay and loss, which affects 2-3% of users within the first year 3, 4.
Documentation and Counseling
Inform patients that these dental problems can develop even with good oral hygiene, emphasizing the importance of the post-dose rinsing protocol. Document that you provided this FDA-mandated warning 1. Ensure patients understand this is a known medication effect requiring active prevention, not a reason to avoid treatment.